MedTrace Logo

CAR T Cells Real World Evidence Study Based on the French Hospital Claims Data Source (PMSI)

NCT05349201 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 273

Last updated 2022-07-01

No results posted yet for this study

Summary

This was a Retrospective cohort study based on the PMSI data source

Conditions

  • Diffuse Large B-Cell Lymphoma (DLBCL)
  • Acute Lymphoblastic Leukemia (ALL)

Interventions

OTHER

KYMRIAH

Patients (≥18 years of age) with (relapsed/refractory diffuse large B cell lymphoma \[R/R DLBCL\]) or Pediatric and young adult patients (≤25 years of age) with B cell acute lymphoblastic leukemia (ALL) refractory, in relapse post transplant or in second or later relapse

OTHER

YESCARTA

Patients (≥18 years of age) with (relapsed/refractory diffuse large B cell lymphoma \[R/R DLBCL\])

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Eligibility

Min Age
18 Years
Max Age
30 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-12-09
Primary Completion
2021-05-28
Completion
2021-05-28

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05349201 on ClinicalTrials.gov